Navigation Links
OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
Date:8/30/2007

Private offering provides new funding as OncoVista, Inc. takes steps

towards public reporting status.

SAN ANTONIO, Aug. 30 /PRNewswire/ -- OncoVista, Inc., a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies with improved efficacy and reduced toxicity, announced the successful completion of a private placement offering and its acquisition of a control position in a public reporting shell company.

OncoVista completed the private sale of 970,712 units of common stock and warrants to new and existing investors raising approximately $6.8 million in gross proceeds. Participants in the offering included Wexford Capital LLC, CAMOFI Master LDC, Bristol Investment Fund, Ltd., as well as other select institutional and qualified investors. Maxim Group, LLC acted as the company's exclusive placement agent in the offering. Contemporaneously with the closing, OncoVista acquired a control position in Aviation Upgrade Technologies, Inc., a Nevada corporation (OTC Bulletin Board: AVUG) and transferred the former operating subsidiary to its former chief executive officer.

"The closing of our financing and our acquisition of a public reporting company in preparation for our becoming a publicly-traded company marks a very exciting and important milestone in OncoVista's history," said Alexander L. Weis, Ph.D., Chairman of the Board of Directors, President and Chief Executive Officer of OncoVista, Inc. "Targeted oncology therapy is an attractive and growing business segment, and our ability to access the public capital market is a tremendous opportunity for further growth of OncoVista," Dr. Weis said.

About OncoVista, Inc.

A biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies both through the acquisition of rights to technologies and drugs from others and through the development of proprietary products. OncoVista intends to identify, develop and rapidly commercialize innovative therapies for safe and efficacious treatment of cancer. By commercializing novel therapeutics, OncoVista plans to capture a significant share of the U.S. market for cancer therapeutics, currently estimated at $32 billion per year and projected to grow to $70 billion by 2010. In addition, OncoVista's proprietary diagnostic technology is expected to facilitate selection of clinical trial participants, as well as to quantify and predict the response of patients to treatment. OncoVista believes that the development of targeted approaches to the administration of anticancer agents will lead to improved outcomes and/or reduced toxicity.


'/>"/>
SOURCE OncoVista, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. NimbleGen closes $8.2m venture round, bringing total to $50m
2. BoneCare doubles options and profits as fiscal year closes
3. DEMO 2003 Closes with Focus on Collaboration and Communication
4. Venture Investors early-stage fund grows to $115 million
5. Two convicted of selling $6 million in counterfeit Rockwell software on eBay
6. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
7. TomoTherapy raises $223 million in IPO
8. Fiserv reports $113.5 million in Q1 profit
9. Investors raise $25 million for biodiesel plant
10. Grow Milwaukee includes millions for tech funding
11. Mirus Bio, Pfizer enter multimillion-dollar research agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program ... honoring scientists who have made outstanding contributions to analytical chemistry and ... 2018, the world’s leading conference and exposition for laboratory science, which will be ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series will ... American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population estimates ... of how to continue to feed a growing nation. At the same time, many ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving ... marijuana products targeting the needs of consumers who are incorporating medical marijuana into ... in Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving ...
(Date:10/7/2017)... Phoenix, Arizona (PRWEB) , ... ... ... than 15 years’ experience providing advanced instruments and applications consulting for microscopy ... the in-house expertise in application consulting, Nanoscience Analytical offers a broad range ...
Breaking Biology Technology:
(Date:5/16/2017)...   Bridge Patient Portal , an enterprise ... EMR Systems , an electronic medical record solutions ... established a partnership to build an interface between ... Centricity™ products, including Centricity Practice Solution (CPS), Centricity ... new integrations will allow healthcare delivery networks using ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
Breaking Biology News(10 mins):